1. ProANP31-67 ameliorates adverse cardiac remodeling and improves systolic and diastolic functions in a preclinical model of cardiorenal syndrome. (10th June 2022) Authors: Silva, GJJ; Parvan, R; Shen, X; Frisk, M; Altara, R; Strand, ME; Rypdal, KB; Lunde, IG; Louch, WE; Aronsen, JM; Stenslokken, K-O; Stokke, MK; Cataliotti, A Journal: Cardiovascular research Issue: Volume 118(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CaMKII as a therapeutic target in catecholaminergic polymorphic ventricular tachycardia type 1. (24th May 2021) Authors: Sadredini, M; Manotheepan, R; Haugsten Hansen, M; Frisk, M; Louch, WE; Lehnart, SE; Anderson, ME; Sjaastad, I; Stokke, MK Journal: Europace Issue: Volume 23:Supplement 3(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗